
Sunrun Stock To $7?
Sunrun (NASDAQ: RUN) is the leading residential solar installer in the U.S. based on market share. The company's position has become increasingly unstable due to a mix of policy changes, financial pressures, and shifting market dynamics.
There's more to consider – With a market capitalization of $2.5 billion, Sunrun has experienced a 36% loss of value over the last year. Investors need to recognize the company's susceptibility to economic downturns, which was evident during the Covid-19 crisis when its stock fell by about 40% in just a few quarters. This historical context raises the possibility that Sunrun's current share price of $11 might decline to approximately $7 if similar market conditions arise again. Nevertheless, for investors aiming for lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative, having outperformed the S&P 500 and delivered returns that exceed 91% since its inception. Separately, see Is Intel Stock A Buy Now?
Why Is It Relevant Now?
Recent actions from both the legislative and executive branches have sped up the expiration of important federal tax credits—namely, the 25D Residential Solar Credit and the 48E Investment Tax Credit—shortening the opportunity for Sunrun to take advantage of these vital incentives. An executive order enacted on July 8 complicates the situation further by redefining the term 'under construction,' introducing new compliance challenges. Concurrently, the imposition of substantial tariffs on imported solar equipment jeopardizes cost structures and profit margins.
These changes fundamentally impact Sunrun's business model, which heavily relies on tax credits to back its leasing and power purchase agreements. As these incentives wane and operational costs escalate, the company's capability to sustain competitive pricing and profitability is increasingly at risk.
How resilient is RUN stock during a downturn?
Historically, Sunrun has lagged behind the S&P 500 during market downturns, underscoring its vulnerability to macroeconomic shocks. In the 2022 inflation-driven selloff, RUN tumbled 67.4%, significantly worse than the S&P 500's 25.4% decline, and it has not yet regained its previous highs, presently trading around $10.90. In the downturn triggered by Covid, RUN dropped 38.7% but bounced back swiftly. While the stock can recover, its historical performance indicates high volatility and limited downside resilience. Our dashboard How Low Can Stocks Go During A Market Crash captures the performance of key stocks during and after the last six market crashes.
Protecting Wealth
No longer merely a solar stock, Sunrun now serves as a high-stakes indicator of the trajectory for rooftop solar as federal policy shifts become less predictable. Although the company is actively adapting—expanding into energy storage, changing billing models, and tweaking its supply chain—investors continue to be concerned about the pace and effectiveness of these strategic adjustments. With increasing regulatory challenges and expiring incentives, the market is closely monitoring whether Sunrun can adjust quickly enough to maintain growth and protect its margins.
RUN stock is currently trading at 1.1x price-to-sales, below its 3-year average of 1.5x and considerably less than the S&P 500 average of 3.1x. While this might imply a discount, it does not categorize it as 'deep value.' Sunrun continues to be valued as a growth company, and when growth appears uncertain, justifying that premium becomes more difficult. Considering the wider economic uncertainties, ask yourself the question: Do you wish to retain Sunrun stock now? Would you feel compelled to sell if it begins to decline to $8, $7, or even lower? Holding onto a declining stock is never easy. Trefis collaborates with Empirical Asset Management—a Boston-based wealth manager—whose asset allocation strategies yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Empirical has integrated the Trefis HQ Portfolio into this asset allocation strategy to offer clients better returns with reduced risk compared to the benchmark index; providing a less turbulent experience, as demonstrated in the HQ Portfolio performance metrics.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Why SanDisk Stock Slumped on Monday
Edgewater Research just warned of falling prices and falling demand for computer memory in the year's second half. SanDisk isn't in a great place to receive this news, with its stock already unprofitable. If SanDisk can survive 2025, however, profits could return in 2026. 10 stocks we like better than Sandisk › Shares of computer semiconductor memory maker SanDisk (NASDAQ: SNDK) tumbled 8.3% through 12:15 p.m. ET Monday. You can probably blame Edgewater Research for that. We don't yet know everything about Edgewater's report on Micron. All I've been able to learn is that has a very short write-up today advising that Edgewater thinks demand and pricing for computer memory in the first half of 2025 was "better" Maybe better than last year. Maybe better than Edgewater was expecting. Maybe better than what other analysts were forecasting. Now the bad news: Demand and pricing will be "sub seasonal" in the second half of this year, says Edgewater, and with a "bias lower." That implies things may be getting worse, not better. Edgewater says this is true for both SanDisk (NASDAQ: SNDK) and for its rival Micron (NASDAQ: MU), by the way. So how much should this all worry you, if you own SanDisk stock? Quite a lot, at least in the short term. SanDisk was already unprofitable, with losses amounting to $1.5 billion over the last 12 reported months. Investors were already braced for bad news this year, with analysts forecasting losses of $1.4 billion. Now that number might be getting even worse. The good news is that SanDisk is expected to turn profitable again next year, earning perhaps $607 million. That would give the stock a P/E ratio of about 11 on 2026 earnings, versus its current P/E based on earnings that are still negative. If the stock sells off hard on Edgewater's latest report, and if you're patient enough to wait for this to improve next year, now might be a good time to buy this cyclical semiconductor stock. Before you buy stock in Sandisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Sandisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 14, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why SanDisk Stock Slumped on Monday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Merck to Acquire Verona for $10 Billion, Targeting Life Beyond Keytruda
Merck (MRK, Financials) is spending $10 billion to acquire U.K.-based Verona Pharma, the company announced Wednesday; the move is part of Merck's push to diversify its drug portfolio as its blockbuster cancer drug Keytruda approaches major patent cliffs starting in 2028. Warning! GuruFocus has detected 3 Warning Sign with MRK. Verona brings with it Ohtuvayre, an inhaled treatment for chronic obstructive pulmonary disease, often known as smoker's lung. The drug was approved earlier this year and has generated $42.3 million in sales so far in 2024; analysts see long-term potential, estimating peak annual revenue could top $3 billion. Merck will pay $107 per American depository sharerepresenting a 23% premium to Verona's last Nasdaq close. Shares of Verona surged 20% in premarket trading following the announcement; Merck edged slightly higher. This is Merck's largest deal since its $10.8 billion acquisition of Prometheus Biosciences in 2023 and adds to its growing pipeline of late-stage assets. The company has made a string of acquisitions since 2021, including the $11.5 billion Acceleron deal, which brought in Winrevaira treatment for pulmonary arterial hypertension. While analysts generally welcomed the Verona deal, some flagged that Merck still has work to do to assure investors it can offset looming Keytruda losses. This looks like a potential complementary therapy, said Kevin Gade of Bahl & Gaynor. But others, like BMO Capital's Evan Seigerman, noted that one acquisition won't be enough to fully bridge the gap. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
China's 4.2 Trillion Yuan Lending Spike: Stimulus Firepower or Economic Red Flag?
China's credit engine just kicked into high gearbut it's not the full story. Total social financing hit 4.2 trillion yuan ($585.7 billion) in June, coming in well above economists' expectations. Banks extended 2.2 trillion yuan in new loans, thanks to a seasonal lending push and a wave of government bond issuance. The People's Bank of China doubled down on its moderately loose stance, signaling it will maintain ample liquidity while monitoring the impact of existing measures. Officials say the goal is to stimulate demand and stabilize investor sentimentbut so far, private sector appetite still looks soft. Warning! GuruFocus has detected 3 Warning Sign with MRK. Take a closer look and cracks start to show. ING's Lynn Song noted that the credit bump was heavily propped up by government bond sales, not organic business borrowing. Property remains a key drag: new-home sales from China's top 100 developers dropped 23% in June year-over-year, steeper than May's 8.6% decline. While interbank borrowing costs have eased, and liquidity is flowing, the real economy hasn't caught uplending growth in the first half of 2025 still paints a picture of weak confidence and subdued risk-taking. So what does it mean for global investors? For companies tethered to Chinese demandlike Tesla (NASDAQ:TSLA)this rebound in headline credit may look promising, but the story underneath remains complex. Unless wage growth stabilizes and consumer confidence picks up, the credit tap alone may not be enough to drive a lasting recovery. Eyes now turn to whether China's next round of stimulus can translate into real-world spendingand whether the private sector is ready to step off the sidelines. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data